Immunotherapy of melanoma: a critical review of current concepts and future strategies - PubMed (original) (raw)
Review
Immunotherapy of melanoma: a critical review of current concepts and future strategies
Adam I Riker et al. Expert Opin Biol Ther. 2007 Mar.
Abstract
Advanced melanoma is a devastating disease with a very poor overall prognosis. There are only two agents that are approved by the FDA for use in patients with metastatic melanoma: dacarbazine and IL-2. Both agents have an overall response rate well below 20%, with only rare long-term responders noted. Metastatic melanoma is known to be one of the most resistant cancers to a plethora of treatment modalities, such as single-agent and combination chemotherapy, chemoimmunotherapy and immunotherapy with a host of immune stimulators. Indeed, researchers worldwide have recognized the lack of effective therapies and have refocused their efforts on developing novel and cutting-edge strategies of treatment. This is based on an improved understanding of the complex interactions that occur within the tumor microenvironment, and the central role that the host immune system plays in the surveillance of cancer. This review summarizes the recent results of novel immunotherapeutic regimens and focuses on cutting-edge modalities of treatment that encompass new lines of thinking in the war against cancer and, in particular, melanoma.
Similar articles
- Immunotherapy as part of a multidisciplinary approach to melanoma treatment.
Riker AI, Jove R, Daud AI. Riker AI, et al. Front Biosci. 2006 Jan 1;11:1-14. doi: 10.2741/1775. Front Biosci. 2006. PMID: 16146709 Review. - Immunotherapy as an adjuvant therapy in the management of advanced, surgically resected, melanoma.
Kalani AD, Jack A, Montenegro G, Degliuomini J, Wallack MK. Kalani AD, et al. G Ital Dermatol Venereol. 2008 Feb;143(1):59-70. G Ital Dermatol Venereol. 2008. PMID: 18833052 Review. - Combined chemoimmunotherapy in metastatic melanoma--is there a need for the double?
Schrader AJ. Schrader AJ. Anticancer Drugs. 2000 Mar;11(3):143-8. doi: 10.1097/00001813-200003000-00001. Anticancer Drugs. 2000. PMID: 10831272 Review. - Interleukin-2-based immunotherapy and chemoimmunotherapy in metastatic melanoma.
Keilholz U, Scheibenbogen C, Brossart P, Möhler T, Tilgen W, Hunstein W. Keilholz U, et al. Recent Results Cancer Res. 1995;139:383-90. doi: 10.1007/978-3-642-78771-3_29. Recent Results Cancer Res. 1995. PMID: 7597305 Clinical Trial. - Next generation of immunotherapy for melanoma.
Kirkwood JM, Tarhini AA, Panelli MC, Moschos SJ, Zarour HM, Butterfield LH, Gogas HJ. Kirkwood JM, et al. J Clin Oncol. 2008 Jul 10;26(20):3445-55. doi: 10.1200/JCO.2007.14.6423. J Clin Oncol. 2008. PMID: 18612161 Review.
Cited by
- Skin tumor responsiveness to interleukin-2 treatment and CD8 Foxp3+ T cell expansion in an immunocompetent mouse model.
Foureau DM, McKillop IH, Jones CP, Amin A, White RL, Salo JC. Foureau DM, et al. Cancer Immunol Immunother. 2011 Sep;60(9):1347-56. doi: 10.1007/s00262-011-1035-1. Epub 2011 Jun 3. Cancer Immunol Immunother. 2011. PMID: 21638127 Free PMC article. - Membrane anchored immunostimulatory oligonucleotides for in vivo cell modification and localized immunotherapy.
Liu H, Kwong B, Irvine DJ. Liu H, et al. Angew Chem Int Ed Engl. 2011 Jul 25;50(31):7052-5. doi: 10.1002/anie.201101266. Epub 2011 Jun 17. Angew Chem Int Ed Engl. 2011. PMID: 21688362 Free PMC article. No abstract available. - Bioelectric applications for treatment of melanoma.
Beebe SJ, Schoenbach KH, Heller R. Beebe SJ, et al. Cancers (Basel). 2010 Sep 27;2(3):1731-70. doi: 10.3390/cancers2031731. Cancers (Basel). 2010. PMID: 24281185 Free PMC article. - Interleukin-37 improves T-cell-mediated immunity and chimeric antigen receptor T-cell therapy in aged backgrounds.
Hamilton JAG, Lee MY, Hunter R, Ank RS, Story JY, Talekar G, Sisroe T, Ballak DB, Fedanov A, Porter CC, Eisenmesser EZ, Dinarello CA, Raikar SS, DeGregori J, Henry CJ. Hamilton JAG, et al. Aging Cell. 2021 Feb;20(2):e13309. doi: 10.1111/acel.13309. Epub 2021 Jan 22. Aging Cell. 2021. PMID: 33480151 Free PMC article. - The relationship of arginine deprivation, argininosuccinate synthetase and cell death in melanoma.
Savaraj N, Wu C, Kuo MT, You M, Wangpaichitr M, Robles C, Spector S, Feun L. Savaraj N, et al. Drug Target Insights. 2007;2:119-28. Epub 2007 Jun 15. Drug Target Insights. 2007. PMID: 21901069 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical